Related Experiment Video

Updated: Jun 18, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Efficacy and safety of benralizumab in elderly patients with severe eosinophilic asthma

Kohei Somekawa¹, Keisuke Watanabe¹, Kenichi Seki²

¹Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Kanazawa-ku, Japan.

European Clinical Respiratory Journal

|July 30, 2024

Abstract

Background:

Biologics are the important drugs for severe asthma, but clinical trials included few elderly patients. Data on the safety and efficacy of benralizumab in elderly asthma patients are limited.

Methods:

This clinical study was a multicentre, retrospective, observational study at two hospitals. Patients aged ≥18 years diagnosed with severe asthma treated with benralizumab were included. Elderly patients were defined as those aged 70 years or older. Efficacy and safety were then analyzed in elderly and non-elderly patients. The primary endpoints were the annual number of asthma exacerbations for efficacy and the discontinuation rate due to adverse events for safety.

Results:

Between August 2016 and October 2022, 61 patients were enrolled; 10 patients were excluded, and 51 (22 elderly, 29 non-elderly) patients were analyzed. In elderly patients, the annual number of asthma exacerbations before treatment with benralizumab (pre-benralizumab) was 3.78, and the number during treatment with benralizumab was 1.26, a decrease of 2.52 (95% confidence interval [CI], 1.3 to 3.74, p < 0.001). In non-elderly patients, the annual number of asthma exacerbation in the pre-benralizumab period was 3.24, and during treatment with benralizumab it was 0.68, a decrease of 2.56 (95% CI, 1.3 to 3.82, p < 0.001). There was no significant difference in discontinuation due to treatment-related adverse events (elderly vs non-elderly, 2 (9%) vs 0 (0%), p = 0.18).

Conclusion:

Benralizumab reduced the annual number of asthma exacerbations and was well tolerated in elderly patients.

Keywords:

Asthma adverse event benralizumab biologics elderly patients

More Related Videos

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Published on: May 30, 2020

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Antiasthma Drugs: β2-Adrenoceptor Agonists

Antiasthma Drugs: β₂-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...

Antiasthma Drugs: Methylxanthines

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...

Drugs Used in Lower Respiratory Disorders: Overview

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

Articles linked to this work by shared authors, journal, and citation graph.

Adding the Short Physical Performance Battery to a Fall Risk Score for Time-Dependent Prediction of Falls in Older Inpatients: A Retrospective Observational Study.

Geriatrics & gerontology international·2026

Imiquimod triggers TLR7-independent apoptosis but TLR7-dependent activation in murine CD4+ T cells.

Biochemical and biophysical research communications·2026

Clinical Impact of HRCT UIP Pattern Among Patients With Idiopathic Pulmonary Fibrosis Undergoing Antifibrotic Treatment: A Multicenter Retrospective Observational Study.

Canadian respiratory journal·2026

Lactate dehydrogenase-to-lymphocyte ratio predicts overall and progression-free survival among patients with advanced small-cell lung cancer receiving first-line chemoimmunotherapy: A two-center retrospective observational study.

Medicine·2026

Pleuroparenchymal fibroelastosis-like findings identify an idiopathic pulmonary fibrosis subgroup with shortened telomeres and poor prognosis.

ERJ open research·2026

A case of advanced esophagogastric junction cancer in which comprehensive genomic profiling by liquid biopsy led to the diagnosis of a second primary hepatocellular carcinoma.

International cancer conference journal·2026

See all related articles